头孢哌酮/舒巴坦对呼吸机相关性肺炎的临床疗效

Clinical efficacy of cefoperazone/sulbactam in treatment of ventilator-associated pneumonia

目的观察头孢哌酮/舒巴坦对呼吸机相关性肺炎（VAP）的临床疗效和安全性。方法符合诊断标准的VAP患者60例,在常规治疗的基础上加用头孢哌酮/舒巴坦治疗：每8小时静脉滴注3.0g,疗程10～14d。观察疗效,记录药物相关不良反应。结果治疗后,痊愈16例,显效24例,进步14例,无效6例;总有效率为66.7%。结论对于早发性或迟发性VAP,在常规治疗的基础上加用头孢哌酮/舒巴坦均具有良好的疗效,无明显药物相关不良反应。

Objective To observe the clinical efficacy and safety of cefoperazone/sulbactam in the treatment of ventilator-associated pneumonia（VAP）.Methods On the basic treatments,sixty patients with VAP confirmed by the guideline to diagnosis and treatment of hospital acquired pneumonia were intravenously injected with cefoperazone/sulbactam 3.0g every 8hours for 10 to 14days.The clinical efficacy was evaluated and drug-related adverse effects were recorded.Results After treatment with cefoperazone/sulbactam,16 patients were cured,24 patients were markedly effective,14 patients were improved,and 6patients were ineffective.The total effectiveness rate was 66.7%.Conclusion On the basic treatments,the treatment with cefoperazone/sulbactam is effective in treating VAP patients early and late onset without drug-related adverse effects.